Marketing Authorization of Pharmaceutical Products with Special Reference to Multisource (Generic) Products: A Manual for Drug Regulatory Authorities - Regulatory Support Series No. 005
(1998; 213 pages)
Table of Contents
View the documentPREFACE
View the documentI. INTRODUCTION
Open this folder and view contentsII. PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL
Open this folder and view contentsIII. OPERATING ACTIVITIES
Open this folder and view contentsIV. REVIEW OF APPLICATIONS FOR MARKETING AUTHORIZATION OF MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS
View the documentV. ISSUE OF WRITTEN MARKETING AUTHORIZATION
View the documentVI. VARIATIONS
View the documentVII. PERIODIC REVIEWS
View the documentVIII. SUSPENSION AND REVOCATION OF MARKETING AUTHORIZATION
View the documentGLOSSARY
View the documentABBREVIATIONS
View the documentREFERENCES
Close this folderANNEXES
Open this folder and view contentsAnnex 1: National drug regulatory legislation: guiding principles for small drug regulatory authorities1
Open this folder and view contentsAnnex 2: *Guidelines for Implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce1
Open this folder and view contentsAnnex 3: *Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability1
View the documentAnnex 4: Model Guidelines on Conflict of Interest and Model Proforma for a Signed Statement on Conflict of Interest
View the documentAnnex 5: Model Contract between a Regulatory Authority and an External Evaluator of Chemistry, Pharmaceutical and Bioavailability Data
View the documentAnnex 6: Model Application Form for new Marketing Authorizations, Periodic Reviews and Variations, with Notes to the Applicant
View the documentAnnex 7: Detailed Advice on Evaluation of Data by the Drug Regulatory Authority
Open this folder and view contentsAnnex 8: Ethical criteria for medicinal drug promotion1
View the documentAnnex 9: Model marketing authorization letter
View the documentAnnex 10: Model List of Variations (Changes) to Pharmaceutical Aspects of Registered Products which may be made without Prior Approval
Open this folder and view contentsAnnex 11: *Guidelines for stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms1
 

Annex 9: Model marketing authorization letter

The Managing Director

[Name of company]

[Address]

[Date]:

Attention: Regulatory Affairs Manager

Dear Sir/Madam

I refer to the application dated [date of application] for marketing authorization of:

Proprietary name (trade name)
Approved generic name(s)
Strength(s) per dosage unit
Dosage form
Name of authorization holder*
[*Must be a person or company in the country in which marketing is being authorized. This letter should normally be addressed to the marketing authorization holder.]

Evaluation of the application has been completed. Approval under [name of legislation] is granted, subject to the conditions in this letter and its attachments. This letter and its attachments constitute the marketing authorization. The details of this marketing authorization are as follows.

Marketing authorization number

Date from which marketing is authorized

Expiry date of this marketing authorizations

The conditions which apply are as follows..

General conditions applying to all products

X The product(s) must conform with all the details provided in your application and as modified in subsequent correspondence.

X No changes may be made to the product without prior approval, except for changes of the type listed in [name of regulatory authority]’s policy on “Changes to pharmaceutical aspects which may be made without prior approval”. Conditions in that policy apply.

X The approved sites of manufacture are those in Attachment 1.

X The approved shelf-life is that in Attachment 2.

X The only Product Information (PI) that may be supplied with or for this product must be the PI that is approved. Attachment 3 is a copy of the approved PI.

X The Product information may not be altered without prior approval, except for safety updates that further restrict use of the product. Any such safety-related changes must be notified to [name of regulatory authority] within five days of making the change.

X The product information must include the marketing authorization number and the date from which marketing is authorized. This information must appear in the top right hand corner of the first page of the Product information, in letters of at least 1.5 mm tall.

X All advertising and promotion of the product(s) must be consistent with the agreed product information.

X Additional specific conditions applying to this product:

X [...for example, “Distribution is restricted to hospitals specializing in oncology”.......]

X [...........................................................................................................................]

X [...........................................................................................................................]

If you have any doubt as to the meaning of this letter and its attachments, you should contact the undersigned prior to marketing the product.

Yours faithfully

[Name]
[Signature]

AUTHORIZED PERSON UNDER [name of legislation]

MARKETING AUTHORIZATION
Attachment 1

Product

Proprietary name (trade name)

Approved generic name(s)

Strength(s) per dosage unit

Dosage form

Name of authorization holder

Marketing authorization number

Date from which marketing is authorized

Expiry date of this marketing authorization

The approved manufacturers are as follows.

Production stage

Name of site

Street address of site

Manufacturing step

[Active pharmaceutical ingredient I ]

   

Production

[Active pharmaceutical ingredient II ]

   

Production

Finished product

   

[For example granulation]

     

[For example sterilization]

     

[For example packaging]

     

[For example quality control]

MARKETING AUTHORIZATION
Attachment 2

Product

Proprietary name (trade name)

Approved generic name(s)

Strength(s) per dosage unit

Dosage form

Name of authorization holder

Marketing authorization number

Date from which marketing is authorized

Expiry date of this authorization

Shelf-life

The approved shelf-life of this product when packaged and labelled as detailed in the application and modified in subsequent correspondence is as follows.

Pack

Shelf-life

Storage conditions

[For example, PVC/Al blisters, 25 and 50 tablets per blister]

18 months

Store below 30EC
Protect from moisture

[For example, HDPE bottles]

3 years

Store below 30EC
Protect from moisture

Restrictions on sale or distribution

[Normally one of these, and possibly different restrictions for different strengths.

X Scheduled narcotic;

X Restricted prescription-only distribution (specify - for example, hospitals only);

X Prescription only;

X Pharmacy only;

X Over the counter (OTC)].

to previous section to next section
 

Last updated: April 24, 2012